Internet Vikings Celebrate Their 14th Anniversary by Receiving Prestigious Global Gaming Awards

The week before, global iGaming hosting solutions supplier Internet Vikings received the Services Provider of the Year award by Global Gaming Awards (GGA), acknowledging the company’s achievements and input into the industry.

Publicerad: 25 april 2022, 09:53

Internet Vikings International AB

“I could not be more proud”, said Internet Vikings’ co-founder and CCO, Rickard Vikström. “The entire team has worked hard to help our company rise to the level it is at today. To us the award is more than a status. It means that the iGaming industry sees and recognises the value we bring to the businesses.”

Internet Vikings originated in Stockholm in 2008. Over the years the Swedish IT company kept adding new products, including a variety of costomizable hosting services specific to certain industries and countries. Eventually turning into a leading hosting services provider.

Today, Internet Vikings is a global brand operating from 5 countries and servicing clients across 5 continents: Europe, North and South America, Asia and Australia, with special focus in the iGaming industry and the U.S. Servicing their clients in almost every state where online gaming and sports betting are legal.

The company CEO Peter Ekmark supported Rickard’s words by adding: “This event gave us additional confirmation that we are on the right track. We will continue contributing to the growth of our clients and the industry itself through our services. Leading with creativity, innovation and transformation needed to build a better online gaming and sports betting experience.”

For press inquiries please contact Julija Lavosnik
+35699998020
julija.lavosnik@internetvikings.com

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på Di.se?
Läs mer om publicering på Di.se

Internet Vikings International AB

Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation

30 patients with active or chronic active antibody mediated rejection (AMR) episodes post kidney transplantation have been enrolled and randomized 2:1 to imlifidase v.s. standard-of-care
Completion of enrollment marks an important milestone for Hansa, as the company explores the potential of imlifidase in the post transplantation setting.
Acute AMR episodes post kidney transplantation occur in 5-7% of patients, with significant risk of patients losing graft function. There is no approved treatment for preventing and treating AMR.

Publicerad: 23 maj 2022, 08:00

Hansa Biopharma AB

Lund, Sweden May 23, 2022. Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces the completion of enrollment in its phase 2 study evaluating safety, tolerability and efficacy of imlifidase in patients with active and chronic active antibody mediated rejection (“AMR”) episodes. A first data read out is expected in the second half of 2022, as previously guided.

“The on-time completion of enrollment in the AMR phase 2 study is an important milestone in the clinical development of imlifidase for this patient population and is a testimony to our commitment to develop potentially life-saving and life-altering therapies for patients with rare immunological diseases with significant unmet medical need”, says Christian Kjellman, Chief Science Officer, Hansa Biopharma. “Long-term graft survival is challenged by AMR post kidney transplantation, and imlifidase has the potential to have a meaningful positive impact for these patients and the healthcare system at large.”

Acute AMR post kidney transplantation is a serious condition that occurs in 5-7% of kidney transplants and is a significant challenge to long-term graft survival. AMR, is the main cause of graft dysfunction and loss after kidney transplantation. In the U.S. and Europe, approximately 45,000 patients receive kidney transplants annually, and approximately 400,000, currently live with a kidney transplant.

The AMR phase 2 program is a randomized, open-label, multi-center, controlled study, that has enrolled a total of 30 AMR patients across centers in France, Germany, Austria, Australia, and the U.S. This study is designed to evaluate the safety and efficacy of imlifidase in eliminating donor specific antibodies (“DSAs”) in acute AMR patients, post transplantation. Twenty individuals have been randomized to receive imlifidase treatment comprised of one intravenous dose of 0.25mg/kg, while 10 individuals in the active control arm received 5-10 sessions of plasma exchange. Efficacy and safety is monitored over a six-month period post treatment.

More information about the trial is available at ClinicalTrials.gov under NCT03897205 (2019).

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

Följande bilagor finns för nedladdning:
20220523 HNSA - PR AMR completion of enrollment FINAL ENG

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på Di.se?
Läs mer om publicering på Di.se

Hansa Biopharma AB